GVHD Clinical Trial
Official title:
The MAGIC Algorithm Probability Guided Preemption of Steroid-refractory Graft-versus-host Disease With Ruxolitinib
Verified date | October 2023 |
Source | Sichuan University |
Contact | Jie Ji, MD |
Phone | 86-28-85422373 |
jieji[@]scu.edu.cn | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this observation study is to test in patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer is: • Effect of MAGIC algorithm probability guided preemption of aGVHD with ruxolitinib on prevention of severe aGVHD. Participants will take ruxolitinib with the dose of 5mg bid for 28 days. If no signs of aGvHD, the dose of ruxolitinib is gradually tapered within the following 16 days. Researchers will compare patients who don't receive preemption of aGVHD with ruxolitinib to see if there is an improvement in severe aGVHD.
Status | Not yet recruiting |
Enrollment | 62 |
Est. completion date | September 30, 2026 |
Est. primary completion date | September 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years to 60 Years |
Eligibility | Inclusion Criteria: - Any donor type (e.g., related, unrelated, haplo) or stem cell source (bone marrow, peripheral blood, cord blood). - Any conditioning regimen (non-myeloablative, myeloablative, or reduced intensity) is acceptable. - GVHD prophylaxis must include a calcineurin inhibitor combined with post transplant cyclophosphamide. - The use of serotherapy to prevent GVHD (e.g., antithymocyte globulin) prior to day 3 post-HCT is permitted - Direct bilirubin must be <2 mg/dL unless the elevation is known to be due to Gilbert syndrome within 3 days prior to enrollment. - ALT/SGPT and AST/SGOT must be <5 x the upper limit of the normal range within 3 days prior to enrollment. - Signed and dated written informed consent obtained from patient or legal representative. Exclusion Criteria: - Patients who develop acute GVHD prior to start of study drug - Patients at very high risk for relapse post HCT as defined by very high disease risk index - Patients participating in a clinical trial where prevention of GVHD is the primary endpoint - Uncontrolled active infection (i.e., progressive symptoms related to infection despite treatment or persistently positive microbiological cultures despite treatment or any other evidence of severe sepsis) - Patients who are pregnant - Patients on dialysis within 7 days of enrollment - Patients requiring ventilator support or oxygen supplementation exceeding 40% FiO2 within 14 days of enrollment. - Patients receiving investigational agent within 30 days of enrollment. However, the Principal Investigator (PI) may approve prior use of an investigational agent if the agent is not expected to interfere with the safety or the efficacy of ruxolitinib |
Country | Name | City | State |
---|---|---|---|
China | West China Hospital, Sichuan University | Chendu | Sichuan |
Lead Sponsor | Collaborator |
---|---|
Sichuan University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of High Risk Patients Who Develop Grade III or IV aGvHD | Number of High Risk Patients Who Develop Grade III or IV aGvHD by day 100 post HCT | Day 100 post HCT | |
Secondary | Number of Participants With Non-relapse Mortality (NRM) | Number of participants with NRM - deaths which could not be attributed to disease relapse or progression. Nonrelapse mortality defined as death without prior relapse at 6 months | 6 months | |
Secondary | Number of Participants With Chronic GVHD Requiring Systemic Steroid Treatment | Number of participants with chronic GVHD requiring systemic steroid treatment. Chronic GVHD Requiring Systemic Steroid Treatment: defined as the development of symptoms of chronic GVHD according to NIH Consensus Criteria that require treatment with oral or intravenous corticosteroids at the end of 1 year and 2 years | 1 year and 2 years | |
Secondary | GvHD free and relapse free survival | Survival of patients without grade 3 or 4 aGvHD or disseminated cGvHD or relapse of disease at end of 1 year post HCT at the end of 1 year and 2 years | 1 year and 2 years | |
Secondary | Progression-free survival | Progression-free survival of this group of patients at the end of 1 year and 2 years | 1 year and 2 years | |
Secondary | Overall survival | Overall survival of this group of patients at the end of 1 year and 2 years | 1 year and 2 years | |
Secondary | Number of Participants With Relapse | Number of participants with relapse at one year and 2 years. Relapse defined as recurrence of disease that required transplant. | 1 year and 2 years | |
Secondary | Number of Participants With Serious Infections | Number of participants with serious infections (defined as grade 3 by the Blood and Marrow Transplant Clinical Trials Network). Serious Infection: Defined as bacterial, fungal, viral or parasitic infections that required oral or intravenous treatments such as antibiotics | 1 year and 2 years | |
Secondary | cytomegalovirus (CMV) reactivation | Number of participants with cytomegalovirus (CMV) reactivation at the end of 1 year and 2 years. CMV reactivation was defined as the presence of DNA copies exceeding 10^3/ml in plasma. | 1 year and 2 years | |
Secondary | grade 2 or higher hemorrhagic cystitis | Number of participants with grade 2 or higher hemorrhagic cystitis at the end of 1 year and 2 years, which was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0). | 1 year and 2 years | |
Secondary | MAGIC algorithm probability (MAP) change | The change in the patient's MAGIC algorithm probability (MAP) at each time | Day 28 post HCT |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02942173 -
CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT
|
Phase 2/Phase 3 | |
Terminated |
NCT01940796 -
Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)
|
Phase 1 | |
Completed |
NCT02066051 -
IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD
|
N/A | |
Not yet recruiting |
NCT05544448 -
In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
|
N/A | |
Completed |
NCT01295710 -
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
|
Phase 3 | |
Not yet recruiting |
NCT06000982 -
Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis
|
Phase 3 | |
Active, not recruiting |
NCT03680092 -
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
|
Phase 2 | |
Not yet recruiting |
NCT06083129 -
Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor
|
Phase 3 | |
Not yet recruiting |
NCT05094765 -
Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD
|
Early Phase 1 | |
Active, not recruiting |
NCT05415410 -
Proof-of-concept Trial of Apraglutide in GVHD
|
Phase 2 | |
Completed |
NCT02441075 -
70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014
|
N/A | |
Completed |
NCT02588339 -
Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention
|
Phase 2 | |
Not yet recruiting |
NCT06334367 -
Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT
|
Phase 2 | |
Completed |
NCT03846479 -
Itacitinib for Low Risk GVHD
|
Phase 2 | |
Completed |
NCT02891603 -
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
|
Phase 1/Phase 2 | |
Completed |
NCT02712762 -
Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) Patients
|
||
Completed |
NCT03945591 -
High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
|
Phase 2 | |
Not yet recruiting |
NCT06411184 -
Safety and Efficacy of Treg Cell in the Treatment of GVHD
|
Phase 1/Phase 2 | |
Terminated |
NCT02338232 -
Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT02156479 -
Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients
|